HCV RNA-dependent RNA polymerase as a target for antiviral development

Current Opinion in Pharmacology

Volumn 2, Issue 5, 2002, Pages 534-540

  Walker, Michelle P ^a   Hong, Zhi ^a  

^a Ribapharm Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(1 CYCLOHEXYL 2 FURAN 3 YL 1H BENZOIMIDAZOLE 5 CARBONYL) AMINO] 3 (1H INDOL 3 YL) PROPIONIC ACID; 2 [4 [4' CHLORO 4 (4 HYDROXY PIPERIDINE 1 CARBONYL) BIPHENYL 2 YLMETHOXY] 2 FLUORO PHENYL] 1 CYCLOHEXYL 1H BENZOIMIDAZOLE 5 CARBOXYLIC ACID; 2' BETA METHYL GUANOSINE; 3' DEOXYCYTIDINE; 5,6 DIHYDROXY 2 [2 (2,4,6 TRICHLORO BENZENESLFONYLAMINO) PHENYL] PYRIMIDINE 4 CARBOXYLIC ACID; ANTIVIRUS AGENT; AZATHIOPRINE; BENZIMIDAZOLE DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; DEOXYCYTIDINE; GUANOSINE DERIVATIVE; GUANOSINE TRIPHOSPHATE; HELICASE; METALLOPROTEINASE; N [5 (4 CHLORO BENZYLIDENE) 4 OXO 2 THIOXO THIAZOLIDIN 3 YL] BENZENESULFONAMIDE; NUCLEOSIDE; PEGINTERFERON ALPHA2A; PROTEOME; REBETRON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RHODANINE; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE; SERINE PROTEINASE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS ENZYME; VIRUS RNA; DNA DIRECTED RNA POLYMERASE; NS 5 PROTEIN, HEPATITIS C VIRUS; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; BIOINFORMATICS; CLINICAL STUDY; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; GENE EXPRESSION PROFILING; GENETIC CODE; GENOME ANALYSIS; GENOMICS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IC 50; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MEDICAL RESEARCH; METHODOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN STRUCTURE; SEQUENCE ANALYSIS; SEQUENCE DATABASE; SEQUENCE HOMOLOGY; VIRUS INHIBITION; VIRUS REPLICATION; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; REVIEW;

ANTIVIRAL AGENTS; DNA-DIRECTED RNA POLYMERASES; HEPACIVIRUS; HUMANS; NUCLEOSIDES; RNA, VIRAL; VIRAL NONSTRUCTURAL PROTEINS;

EID: 0036791538     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(02)00195-9     Document Type: Review

References (49)

1. World Health Organization: Hepatitis C. Seroprevalence of hepatitis C virus (HCV) in a population sample. Wkly Epidemiol Rec 1996, 71:346-349.
2. Monto A, Wright TL: The epidemiology and prevention of hepatocellular carcinoma. Semin Oncol 2001, 28:441-449.
3. Ahmed A, Keeffe EB: Hepatitis C virus and liver transplantation. Clin Liver Dis 2001, 5:1073-1090.
4. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR: The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002, 122:889-896.
5. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R et al.: A randomized, double-blind trial comparing pegylated interferon α-2b to interferon α-2b as initial treatment for chronic hepatitis C. Hepatol 2001, 34:395-403.
6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peg-interferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
7. Di Bisceglie AM, McHutchison J, Rice CM: New therapeutic strategies for hepatitis C. Hepatol 2002, 35:224-231.
8. Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC: Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 1999, 6:937-943.
9. Butcher SJ, Grimes JM, Makeyev EV, Bamford DH, Stuart DI: A mechanism for initiating RNA-dependent RNA polymerization. Nature 2001, 410:235-240.
10. Behrens S-E, Tomei L, De Francesco R: Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J 1996, 15:12-22.
11. Lohmann V, Korner F, Herian U, Bartenschlager R: Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J Virol 1997, 71:8416-8428.
12. Ferrari E, Wright-Minogue J, Fang JW, Baroudy BM, Lau JY, Hong Z: Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli. J Virol 1999, 73:1649-1654.
13. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R: Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285:110-113.
14. Blight KJ, Kolykhalov AA, Rice CM: Efficient initiation of HCV RNA replication in cell culture. Science 2000, 290:1972-1974.
15. Ago H, Adachi T, Yoshida A, Yamamoto M, Habuka N, Yatsunami K, Miyano M: Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Struct Fold Des 1999, 7:1417-1426.
16. Bressanelli S, Tomei L, Roussel A, Incitti I, Vitale RL, Mathieu M, De Francesco R, Rey FA: Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci USA 1999, 96:13034-13039.
17. Bressanelli S, Tomei L, Rey FA, De Francesco R: Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J Virol 2002, 76:3482-3492.
18. Tomei L, Vitale RL, Incitti I, Serafini S, Altamura S, Vitelli A, De Francesco R: Biochemical characterization of a hepatitis C virus RNA-dependent RNA polymerase mutant lacking the C-terminal hydrophobic sequence. J Gen Virol 2000, 81:759-767.
19. Lohmann V, Roos A, Korner F, Koch JO, Bartenschlager R: Biochemical and structural analysis of the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. J Viral Hepat 2000, 7:167-174.
20. Carroll SS, Sardana V, Yang Z, Jacobs AR, Mizenko C, Hall D, Hill L, Zugay-Murphy J, Kuo LC: Only a small fraction of purified hepatitis C RNA-dependent RNA polymerase is catalytically competent: implications for viral replication and in vitro assays. Biochemistry 2000, 39:8243-8249.
21. Schmidt-Mende J, Bieck E, Hugle T, Penin F, Rice CM, Blum HE, Moradpour D: Determinants for membrane association of the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem 2001, 276:44052-44063.
22. Hong Z, Ferrari E, Skelton A, Wright-Minogue J, Zhong W, Lesburg CA: Effects of genotype variations on hepatitis C nonstructural protein 5B structure and activity. In Therapies for Viral Hepatitis. Edited by Schinazi R, Rice CM, Sommadossi JP. Amsterdam: Elsevier Science; 2002, in press.
23. Kao CC, Yang X, Kline A, Wang QM, Barket D, Heinz BA: Template requirements for RNA synthesis by a recombinant hepatitis C virus RNA-dependent RNA polymerase. J Virol 2000, 74:11121-11128.
24. Zhong W, Ferrari E, Lesburg CA, Maag D, Ghosh SK, Cameron CE, Lau JYN, Hong Z: Template/primer requirements and single nucleotide incorporation by hepatitis C virus nonstructural protein 5B polymerase. J Virol 2000, 74:9134-9143.
25. Oh JW, Sheu GT, Lai MM: Template requirement and initiation site selection by hepatitis C virus polymerase on a minimal viral RNA template. J Biol Chem 2000, 275:17710-17717.
26. Lohmann V, Roos A, Korner F, Koch JO, Bartenschlager R: Biochemical and kinetic analyses of NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Virology 1998, 249:108-118.
27. Reigadas S, Ventura M, Sarih-Cottin L, Castroviejo M, Litvak S, Astier-Gin T: HCV RNA-dependent RNA polymerase replicates in vitro the 3′ terminal region of the minus-strand viral RNA more efficiently than the 3′ terminal region of the plus RNA. Eur J Biochem 2001, 268:5857-5867.
28. Pellerin C, Kukolj G: Internal de novo initiation sites of the HCV NS5B polymerase and use thereof. 2001, WO 01/83736 A2.
29. Alaoui-Lsmaili MH, Hamel M, L'Heureux L, Nicolas O, Bilimoria D, Labonte P, Mounir S, Rando RF: The hepatitis C virus NS5B RNA-dependent RNA polymerase activity and susceptibility to inhibitors is modulated by metal cations. J Hum Virol 2000, 3:306-316.
30. Maag D, Castro C, Hong Z, Cameron CE: Hepatitis C virus RNA dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 2001, 276:46094-46098.
31. Shim J-H, Larson G, Wu JZ, Hong Z: Selection of 3′ terminal bases for de novo initiation by HCV RNA-dependent RNA polymerase. J Virol 2002, 76:7030-7039.
32. Luo G, Hamatake RK, Mathis DM, Racela J, Rigat KL, Lemm J, Colonno RJ: De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus. J Virol 2000, 74:851-863.
33. Oh JW, Ito T, Lai MM: A recombinant hepatitis C virus RNA-dependent RNA polymerase capable of copying the full-length viral RNA. J Virol 1999, 73:7694-7702.
34. Zhong W, Uss AS, Ferrari E, Lau JY, Hong Z: De novo initiation of RNA synthesis by hepatitis C virus nonstructural protein 5B polymerase. J Virol 2000, 74:2017-2022.
35. Crotty S, Cameron CE, Andino R: RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci USA 2001, 98:6895-6900.
36. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JYN, Hong Z, Andino R, Cameron CE: The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000, 6:1375-1379.
37. Hong Z, Cameron CE, Walker MP, Castro C, Yao N, Lau JY, Zhong W: A novel mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase. Virology 2001, 285:6-11.
38. Cheetham GM, Jeruzalmi D, Steitz TA: Structural basis for initiation of transcription from an RNA polymerase-promoter complex. Nature 1999, 399:80-83.
39. Cheney IW, Naim S, Lai VCH, Dempsey S, Bellows D, Walker MP, Shim J-H, Horscroft N, Hong Z, Zhong W: Mutations in NS5B polymerase of hepatitis C virus: impacts on in vivo enzymatic activity and viral RNA replication in the subgenomic replicon cell culture. Virol 2002, 297:298-306.
40. Biroccio A, Hamm J, Incitti I, De Francesco R, Tomei L: Selection of RNA aptamers that are specific and high-affinity ligands of the hepatitis C virus bRNA-dependent RNA polymerase. J Virol 2002, 76:3688-3696.
41. Myles DC: Recent advances in the discovery of small molecule therapies for HCV. Curr Opin Drug Discov Dev 2001, 4:411-416.
42. Ismaili HMA, Cheng Y, Lavallee J, Siddiqui A, Storer R: Method for the treatment or prevention of flavivirus infections using nucleoside analogues. 2002, US 02/0019363 A1.
43. Loeb LA, Mullins JI: Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA. 2000, US 6,063,628.
44. Sommadossi JP, Lacolla P: Methods and compositions for treating hepatitis C virus. 2001, WO 01/90121 A2.
45. Gardelli C, Giuliano C, Harper S, Koch U, Narjes F, Ontoria J, Poma M, Ponzi S, Stansfield I, Summa V: Dihydroxypyrimidine carboxylic acids as viral polymerase inhibitors. 2002, WO 02/06246.
46. Jaen J, Peper DE, Powers JP, Walker NP, Li Y: NS5B HCV polymerase inhibitors. 2001, WO 01/77091 A2.
47. Hiromasa H, Kenji M, Hitoshi Y: Fused ring compound and its pharmaceutical application. 2001, JP 01/247550A.
48. Beaulieu PL, Fazal G, Gillard J, Kukolj G: Viral polymerase inhibitors. 2002, WO 02/04425 A2.
49. Laurila MRL, Makeyev EV, Bamford DH: Bacteriophage Φ6 RNA-dependent RNA polymerase. J Biol Chem 2002, 277:17117-17124.